secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001651308-24-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q1 2024 revenue up 82% to $752M; BRUKINSA sales $489M
-------------------------------------------------------------

- Total Q1 product revenue $747M (+82% YoY); total revenue $752M; BRUKINSA revenue $489M.
- BRUKINSA U.S. sales grew 153% and Europe 243% YoY; fifth FDA approval gives broadest BTKi label.
- GAAP operating loss narrowed to $261M from $371M; adjusted operating loss $147M vs $276M.
- TEVIMBRA now approved in U.S. and Europe; advancing late-stage pipeline including sonrotoclax and BTK CDAC.
- Company says progressing toward sustainable profitability with improved operating leverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/0001651308-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000049/bgne-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer